At #ASCPT2024, see model-based pediatric dose recommendations from an ongoing BCR-ABL TKI phase 1/2 trial in patients with #ChronicMyeloidLeukemia PII-100 bit.ly/4ckOcBQ
0
0
0
376
0
Download Image